Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome
Crossref DOI link: https://doi.org/10.1007/s00467-021-04981-5
Published Online: 2021-02-18
Published Print: 2021-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Majeranowski, Alan http://orcid.org/0000-0002-8801-4305
Okrój, Marcin
Text and Data Mining valid from 2021-02-18
Version of Record valid from 2021-02-18
Article History
Received: 13 January 2021
Revised: 14 January 2021
Accepted: 2 February 2021
First Online: 18 February 2021